Kala Bio Inc (NAS:KALA)
$ 6.8575 0.2075 (3.12%) Market Cap: 31.61 Mil Enterprise Value: 19.45 Mil PE Ratio: 0 PB Ratio: 4.61 GF Score: 46/100

Q3 2021 Kala Pharmaceuticals Inc Earnings Call Transcript

Nov 15, 2021 / 03:30PM GMT
Release Date Price: $105 (+1.45%)
Operator

Good morning, and welcome to Kala Pharmaceuticals conference call to review its third quarter financial results and the acquisition of Combangio. Please note that the slide presentation that was designed to accompany this conference call is available on Kala's website, kalarx.com as well as through the webcast player. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals. Please proceed.

Jill S. Steier
Kala Pharmaceuticals, Inc. - Executive Director of IR & Corporate Communications

Thank you, operator, and thank you all for participating in today's call. Earlier today, we issued two press releases: one announcing our third quarter financial results and recent business highlights; and the other announcing our acquisition of Combangio and a fleet asset CMB-012, which we have renamed KPI-012, a novel cell-free secretome therapy currently in clinical development for persistent corneal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot